{
    "clinical_study": {
        "@rank": "124550", 
        "arm_group": {
            "arm_group_label": "Group1:Type 2 diabetic patients treated with Exenatide therapy", 
            "description": "Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label"
        }, 
        "brief_summary": {
            "textblock": "The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the\n      clinical usefulness of Exenatide through collecting, reviewing, identifying and verifying\n      the safety and effectiveness information about Exenatide in general practice."
        }, 
        "brief_title": "Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Male or female at least 18 years of age\n\n          -  Patients who are to initiate Exenatide treatment for type 2 diabetes at baseline,\n             following their treating physicians' advice\n\n          -  Patients, who in the opinion of the treating physicians, comply with all the\n             recommendations stated in the relevant product information\n\n        Exclusion Criteria:\n\n          -  Are simultaneously participating in a different study that includes a treatment\n             intervention and/or an investigational drug\n\n          -  Are pregnant or have intentions of becoming pregnant within the duration of the study\n\n          -  Contraindications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic, hospital and teaching hospitals"
            }
        }, 
        "enrollment": {
            "#text": "1050", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090673", 
            "org_study_id": "MB001-078"
        }, 
        "intervention": {
            "arm_group_label": "Group1:Type 2 diabetic patients treated with Exenatide therapy", 
            "intervention_name": "Exenatide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-756"
                }, 
                "name": "Local Institution"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus", 
            "safety_issue": "Yes", 
            "time_frame": "At 12 weeks \u00b1 4 weeks or 24 weeks \u00b1 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090673"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline to endpoint in Hemoglobin A1c (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 12 or 24 weeks \u00b1 4 weeks"
            }, 
            {
                "measure": "Change from baseline to endpoint in Body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 12 or 24 weeks \u00b1 4 weeks"
            }, 
            {
                "measure": "Change from baseline to endpoint in Fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 12 or 24 weeks \u00b1 4 weeks"
            }, 
            {
                "measure": "Change from baseline to endpoint in subjective measures include improvement of main indication", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 12 or 24 weeks \u00b1 4 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}